Alamar Biosciences stock
ALMRNASDAQAlamar Biosciences, Inc., HealthcareISIN US0109111056
47Score 47 out of 100, Weak
Price and trend
87 / 100
Price history
+44% since 2026The chart shows daily closing prices since 17 Apr 2026, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Normal: the price is neither overheated nor sold off (RSI 53).
The price is 17% below its 52-week high. Largest decline since 17 Apr 2026: 38% (October 2026 to October 2026).
Chart figures for advanced users
- SMA 50$30.25
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$31.76
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)53
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$19.09
- The lowest closing price of the last twelve months.
- Resistance$38.13
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Alamar Biosciences, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $2.21B, is number 126 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 47 out of 100 (Weak): rank 419 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $226.59M, financial debt $42.35M.Stability 53
Weaknesses
- Loss-makingLoss of $55M over the last 12 months.Fundamentals 10
- Volatile share priceVolatility 88% a year over the last 12 months.Stability 53
- Negative free cash flowFree cash flow −$68.58M over the last 12 months.Fundamentals 10
Its standout strengths are momentum and technical analysis, while profitability and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 56%, operating −42%, net −40%. Last 12 months: net −48%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 2 Feb 2027in 82 days
- Last reported
- 3 Nov 2026EPS reported −$0.19 (expected −$0.20)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 39.9% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$1.19−2.2%
- Revenue
- $122.21M+3.1%
- Earnings per share
- −$0.83−39.9%
- Revenue
- $167.84M+1.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +28.5%2026 revenue expected at $116 to $120 million (about 59% growth); the company stated no change versus earlier.
“We expect revenue for full year 2026 to be in the range of $116 million to $120 million, reflecting expected annual growth of 59% at the midpoint of the range.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 10 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $44.56M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Qiming Corporate GP VI, Ltd.Sale
3 Nov 2026, Major holder
- Shares
- 111,313
- Price
- $29.89
- Value
- $3.33M
- Qiming Corporate GP VI, Ltd.Sale
2 Nov 2026, Major holder
- Shares
- 43,930
- Price
- $29.84
- Value
- $1.31M
- Qiming Corporate GP VI, Ltd.Sale
30 Oct 2026, Major holder
- Shares
- 143,706
- Price
- $30.38
- Value
- $4.37M
Show 10 more
- Qiming Corporate GP VI, Ltd.Sale
28 Oct 2026, Major holder
- Shares
- 100,837
- Price
- $32.77
- Value
- $3.3M
- Qiming Corporate GP VI, Ltd.Sale
27 Oct 2026, Major holder
- Shares
- 84,894
- Price
- $31.39
- Value
- $2.66M
- Qiming Corporate GP VI, Ltd.Sale
26 Oct 2026, Major holder
- Shares
- 132,524
- Price
- $30.52
- Value
- $4.04M
- Qiming Corporate GP VI, Ltd.Sale
23 Oct 2026, Major holder
- Shares
- 147,934
- Price
- $30.59
- Value
- $4.53M
- Qiming Corporate GP VI, Ltd.Sale
22 Oct 2026, Major holder
- Shares
- 133,811
- Price
- $29.33
- Value
- $3.92M
- Qiming Corporate GP VI, Ltd.Sale
21 Oct 2026, Major holder
- Shares
- 208,815
- Price
- $30.31
- Value
- $6.33M
- Qiming Corporate GP VI, Ltd.Sale
20 Oct 2026, Major holder
- Shares
- 142,004
- Price
- $27.89
- Value
- $3.96M
- Qiming Corporate GP VI, Ltd.Sale
19 Oct 2026, Major holder
- Shares
- 75,508
- Price
- $26.34
- Value
- $1.99M
- Qiming Corporate GP VI, Ltd.Sale
16 Oct 2026, Major holder
- Shares
- 136
- Price
- $27.02
- Value
- $3,675
- Qiming Corporate GP VI, Ltd.Sale
15 Oct 2026, Major holder
- Shares
- 173,537
- Price
- $27.73
- Value
- $4.81M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Alamar Biosciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Vir BiotechnologyVIR $2.25B52
- Recursion PharmaceuticalsRXRX $2.24B39
- Maze TherapeuticsMAZE $2.24B46
- Vera TherapeuticsVERA $2.2B36
- Maravai LifeSciences HoldingsMRVI $2.19B38
- Lakefront BiotherapeuticsLKFT $2.18B73
- Aurinia PharmaceuticalsAUPH $2.17B69
- First Tracks BiotherapeuticsTRAX $2.12B47
ETFs that hold Alamar Biosciences
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.